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ABSTRACT 
The Main objective of the present study was to enhance the dissolution rate of olanzapine by liquisolid  compact method. Olanzapine is 
practically insoluble in water. Solubility of olanzapine was estimated in different nonvolatile solvents. The study was desig ned to evaluate the 
effect of various formulation parameters like Drug concentration and Excipient ratio on angle of repose and % drug release using 32  full 
factorial design. Quality control tests were done to evaluate each batch of tablets.  Liquisolid compact powder was subjected to angle of repose, 
Carr’s index, and hausner’s ratio to determine flow property. Hardness, friability, disintegration time, drug content, dissolution rate are 
determined. Fourier transforms infrared analysis, x-ray diffraction studies also performed. All the formulations showed acceptable flow 
property and better drug release. The optimized batch was subjected to stability studies for 30 days. The dissolution profile of optimized batch 
was compared with direct compressed tablet and with marketed preparation. Fourier transform infrared spectroscopy conformed that drug 
does not interact with excipients which are added in the formulation. X-ray diffraction study proved that olanzapine (crystalline form) 
converted into amorphous form. From this study it was concluded that liquisolid compact technique improves dissolution rate of olanzapine. 
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INTRODUCTION: 
The active pharmaceutical ingredient in a solid dosage form 
must undergo dissolution before it is available for 
absorption from the gastrointestinal tract. Solubility 
behavior of a drug is one of the key determinants of its 
dissolution and oral bioavailability. In recent years, the 
number of poorly soluble drug candidates has increased 
tremendously. The poor dissolution rate of such water-
insoluble drug is a major impediment to the development of 
pharmaceutical dosage forms. A number of new chemical 
entities do not reach the public merely because of their poor 
oral bioavailability due to inadequate dissolution[1] For 
drugs belonging to Bio-pharmaceutical classification system 
(BCS) class II (poor water solubility and high permeability) 
dissolution rate is often the rate determining step and, which 
determines the rate and degree of absorption. The oral route 
remains the most preferred route of drug administration 
due to its convenience, good patient compliance and low 
production costs. The oral absorption of drugs is often 
controlled by dissolution in the gastrointestinal tract.[2] 
Olanzapine chemically is (2 – methyl 1- 4 - (4 - methyl -1-
piperazinyl)-10H-thieno-[2, 3b], [1, 5] benzodiazepine), a 
thieno benzodiazepine derivative, belongs to class of second 
generation derivative antipsychotic agents, the so-called 
atypical antipsychotics which was approved by the Food and 
Drug Administration. Olanzapine belong to BCS class II 
category i.e., it is inherently highly permeable through 
biological membranes, but exhibits low aqueous solubility. 
The pharmacokinetics of Olanzapine is linear and dose 
proportional within the approved dosage range from 1 mg 
up to 20 mg. The absolute bioavailability is only 
approximately 31.5% due to extensive hepatic metabolism. 
However, its oral bioavailability is very low, probably due to 
poor solubility in water and insufficient dissolution rate. 
Olanzapine is a yellow crystalline solid drug, with higher 
solubility observed in 0.1N HCl.[3-5] 
Different methods are employed to improve the dissolution 
characteristics of poorly water soluble drugs, like 
solubilization, pH adjustment, cosolvents, microemulsion, 
self-emulsification, drug complexation, and particle size 
reduction etc. Amongst these the most promising method for 
promoting dissolution is the use of the liquisolid system. [6] 
This technique of liquisolid preparation is used to formulate 
a drug solution in solid dosage forms. Drug solution is 
generally, prepared by dissolving the drug in non-volatile 
water-miscible solvent. The prepared tablet of liquisolid 
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formulation contains the drug held in solution. The main 
advantages of this technique are Enhanced bioavailability 
can be obtained as compared to conventional tablets, 
Production cost is low compared to soft gelatin capsules. The 
drug is formulated in a tablet form or encapsulated dosage 
form and is held in the solubilized liquid state, which confers 
developed or improved drug wetting properties thereby 
improving drug dissolution profiles. [7] 
The aim of present work is to increase the solubility and in- 
vitro dissolution of practically insoluble drug Olanzapine, by 
formulating into liquisolid tablet consist of Neusilin, Aerosil 
200 as carrier and coating material and PEG 400 as liquid 
vehicle and also to study the influence of various 
formulation parameters on dissolution rate enhancement of 
liquisolid compacts of olanzapine. The in-vitro release of 
such preparations were assessed and in-vitro release of 
optimized batch was compared to that of conventional tablet 
using a USP dissolution apparatus II (paddle) in 900 ml 0.1N 
HCl pH 1.2 for 60 minutes. 
MATERIAL AND METHODS 
The following gift samples were received: Olanzapine 
(Cadila Healthcare Limited., Ahmedabad); Neusilin (Fuji 
Chemicals Ltd., Japan) and Aerosil 200 (Cadila Healthcare 
Ltd., Ahmedabad).  Cross povidone and Polyethylene glycol 
400 (PEG400) is obtained from S.D. Fine Chem Ltd., Mumbai. 
Magnesium stearate and Talc is obtained from Loba Chemie 
Pvt.Ltd., Mumbai. All reagents used were of analytical grade. 
Experimental Methodology 
Preparation of olanzapine standard graph in pH 1.2 
standard buffer [8]: 
Accurately weighed 10 mg of olanzapine was dissolved in 
100 ml volumetric flask containing 10mL of methanol and 
freshly prepared dissolution medium. The obtained solution 
of olanzapine was used as stock solution (100 μg/ mL).  
From the stock solution 0.1,0.2,0.4,0.5,0.6,0.8 and 1 ml were 
withdrawn and diluted to 10 ml with pH 1.2 standard buffer 
to yield concentration of 1,2,4,5,6,8 and 10 μg/mL 
respectively. Absorbance of each solution was measured at 
λmax 259 nm against a reagent blank using Shimadzu 1700 
UV Spectrophotometer and plotting the graph of absorbance 
versus concentration (μg/mL). 
Preparation of olanzapine standard curve in Methanol: 
Accurately weighed 10 mg of olanzapine was dissolved in 
100 mL volumetric flask containing methanol. The obtained 
solution of olanzapine was used as stock solution (100 μg/ 
mL). From the stock solution 0.1,0.2,0.4,0.5,0.6,0.8,1 and 1.2 
ml were withdrawn and diluted to 10 mL with Methanol to 
yield concentration of 1,2,4,5,6,8,10 and 12 μg/mL 
respectively. Absorbance of each solution was measured at 
λmax 270 nm against a reagent blank using Shimadzu 1700 
UV Spectrophotometer. Samples were analyzed in triplicate, 
and the average values were used for plotting the graph of 
absorbance versus concentration (μg/mL). 
Solubility studies [10] 
The solubility of Olanzapine in Distilled water, Glycerine, 0.1 
N HCl, Propylene glycol, PEG 400, Tween 80, SPAN 80 and 
Oleic acid were carried out to evaluate the suitability of the 
non-volatile liquid vehicles as solvent for Olanzapine. 
Saturated solutions were prepared by adding excess amount 
of Olanzapine into 10 ml of each liquid vehicle. The resulting 
solutions were kept in shaker for 48 hr. After this period, the 
solutions were sonicating on the bath sonicator for 1 hour 
and centrifuged. The drug concentration in each supernatant 
was determined using UV spectrophotometer at 270 nm 
after dilution in methanol as appropriate. The concentration 
of Olanzapine in each liquid vehicle was calculated based on 
the calibration curve of Olanzapine in methanol. From these 
results, the solubility of Olanzapine in the respective liquid 
vehicle was calculated. 
Infrared Spectra Analysis [9,11] 
Drug excipient interaction study was carried out by FTIR 
analysis. IR spectra of the Liquisolid system were recorded 
by the KBr pellet method. The spectrum of pure Olanzapine 
and Physical mixture of liquisolid compacts was obtained. 
X-Ray Powder Diffraction (XRPD)  
X-ray diffractograms of pure Olanzapine and Liquisolid 
formulation were studied using Philips Analytical XRD 
instrument. The scanning range was from 5 to 80 at 2 theta 
scale 
Optimal flowable liquid retention potential 
determination for selection of carrier and coating 
material [12] 
The optimal flowable liquid-retention potential (Ф-value) of 
each powder excipient (Neusilin US2, Flocel 101,Methyl 
cellulose, Ethyl Cellulose, Xanthan gum and Aerosil 200) in 
liquid vehicles (PEG 400) were calculated based on the angle 
of slide measurement. Each powder excipient was mixed 
with increasing amounts of liquid vehicle, and the resulting 
liquid/powder admixture was placed on one end of a 
polished metal plate which was tilted gradually until the 
liquid/powder admixture starts to slide. The angle of the 
plate formed with the plane surface during the slide is 
defined as the angle of slide. The Ф-value of excipient in 
different concentrations of liquid vehicles was calculated 
based on equation given below. 
Ф value = Weight of Non-Volatile LiquidVehicle 
               Weight of Solid 
Calculation of Liquid Load Factor (Lf) Required 
Quantities of Carrier (Q) and Coating (q) Materials 
The formulation design was done by using mathematical 
model described by spires et al 
In this study PEG 400, Neusilin US2, Aerosil 200 was used as 
vehicle, carrier, coating material. The concentration of the 
drug solution were taken as 10%, 15%, 20% w/w, and 
carrier coating ratios were taken as 10:1, 15:1, 20:1. 
Ratio of carrier and coating material was calculated by 
R = Q/q 
Where Q is amount of carrier, q is amount of coating 
material. 
Loading factor was determined by adding carrier material to 
drug solution until it produce good flow property and 
compressibility. 
Lf= W/Q 
Where W is weight of liquid medication, Q is weight of 
carrier material. 
Loading factor was also calculated by using Ф-values of 
carrier, coating material and by using R value. 
Lf = Φ + Φ (1/R) 
Once, liquid loading factor was obtained, the appropriate 
quantities of carrier (Q) and coating (q) material required 
were calculated using following equations, 
Q = W/Lf 
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q = Q/R 
Method of preparation of liquisolid systems 
 The drug was initially dispersed in nonvolatile system 
(PEG 400) termed as liquid vehicle at different 
concentration.  
 To this liquid medication, the calculated amount of the 
carrier was added by continuous mixing in the mortar 
and kept for 5-10minutes for complete absorption of 
liquid on carrier material. 
 Then, coating material was added and mixed until 
mortar contents start to look like dry powder. To the 
above binary mixture crosspovidone as disintegrant 
and Magnesium Stearate and Talc were added and 
mixed in mortar.  
 The resultant liquisolid powder is evaluated for flow 
property i.e Angle of repose, Carr’s index and 
Hausner’s ratio.  
 All liquisolid preparations were compacted into tablets 
using a Rotary press tablet machine having flat-faced 
punch with a compression force that provide 
acceptable tablet hardness.  
 The resultant liquisolid tablets were evaluated for 
Thickness, Diameter, Hardness, Friability, Drug 
content, Disintegration and  In vitro dissolution.  
Precompression Evaluation Parameters[13] 
Bulk Density [14] 
An accurately weighed quantity of powder, which was 
previously passed through sieve # 40 and carefully poured 
into graduated cylinder. Then after pouring the powder into 
the graduated cylinder the powder bed was made uniform 
without disturbing. Then the volume was measured directly 
from the graduation marks on the cylinder as ml. The 
volume measured was called as the bulk volume. The bulk 
density was calculated using the formula 
Db =M/Vb 
Where, M is the mass of powder and Vb is bulk volume of 
powder 
Tapped Density 
After measuring the bulk volume the same measuring 
cylinder was set into tap density apparatus. The tap density 
apparatus was set to 300 taps drop per minute and operated 
for 500 taps. Volume was noted as (Va) and again tapped for 
750 times and volume was noted as (Vb). If the difference 
between Va and Vb not greater than 2% then Vb is consider 
as final tapped volume. The tapped density is calculated by 
the following formula 
Dt = M/Vt 
Where, M is the mass of powder and Vt is tapped volume of 
powder 
Angle of Repose:  
It is defined as the angle between the free surfaces of a pile 
of powder to the horizontal plane. The relationship between 
angle of repose and type of flow is shown below. 
Tanθ= h/r 
Where, θ is the angle of repose, h is the height in cms and r is 
the radius in cms  
Table 1: Relation between Angle of Repose and Type of 
Flow 
Angle of repose(ɵ)  Flow property  
25-30  Excellent  
31-35  Good  
36-40  Fair-aid not needed  
41-45  Passable-may hang up  
46-55  Poor-must agitate vibrate  
56-65  Very poor  
>65  Very, very poor  
 
Hausner’s Ratio: 
The prepared liquisolid formulations were weighed and 
poured into a 100 ml cylinder. The poured bulk volume (Vb) 
and the tapped volume (Vt) after 300 taps, was recorded to a 
constant volume, or a tap density tester was used to 
calculate the poured bulk density (Pb) and the tapped 
density (Pt) in g/mL. From the values of bulk density and 
tapped density, Hausner ratio was calculated using the 
following formula. 
Hausner’s Ratio=Tapped density / Bulk density 
Table 2: Relationship between Hausner’s Ratio and Flow 
Property 
Hausner ratio  Flow property  
1.10-1.11  Excellent  
1.12-1.18  Good  
1.19-1.25  Fair  
1.26-1.34  Passable  
1.35-1.45  Poor  
1.46-1.59  Very poor  
>1.60  Very very poor  
 
Percentage Compressibility (Carr’s Index): 
Percentage Carr’s Index (% compressibility) was calculated 
as 100 times the ratio of the difference between the tapped 
density and bulk density to the tapped density. Carr’s index 
(CI) is calculated as follows: 
CI (%) = [(Tapped density – Bulk density) / Tapped density] 
x100 
Table 3: Relation between Carr’s Index and Type of Flow 
Compressibility index (%)  Flow property  
≤10  Excellent  
11-15  Good  
16-20  Fair  
21-25  Passable  
26-31  Poor  
32-37  Very poor  
>38  Very very poor  
 
Post compression evaluation parameters 
a) Weight Variation Test: To study the weight variation, 
twenty tablets were taken and their weight was determined 
individually and collectively using an electronic balance 
Shimadzu, model AX2000, Japan. The average weight of one 
tablet was determined from the collective weight. The 
weight variation test would be a satisfactory method of 
determining the drug content uniformity. The percent 
deviation was calculated using the following formula. 
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% Deviation = (Individual weight – Average weight / 
Average weight) × 100 and the test was performed 
according to the USP official method. 
 b) Crushing Strength  
Hardness of tablet is defined as the force applied across the 
diameter of the tablet in order to break the tablet. The 
resistance of the tablet to chipping, abrasion or breakage 
under condition of storage transformation and handling 
before usage depends on its hardness. Tablet dimension 
(diameter and thickness), and crushing strength of 5 
randomly selected tablets were determined using Dr. 
Schleuniger tablet hardness tester (Pharmatron 8, 
Germany). 
 c) Disintegrating time Apparatus: Electrolab ED-2L 
Disintegration test apparatus 
Media: Distilled water Procedure: The assembly was 
suspended in the specified liquid medium in a 1000 ml 
beaker. The volume of liquid was taken such that when the 
assembly was in highest position the wire mesh was at least 
25 mm below the surface of the liquid and when the 
assembly was in lowest position the wire mesh was at least 
25 mm above the bottom of the beaker. One tablet was 
placed into each of the tube of the assembly and disk was 
added to each tube. The apparatus was operated for 
specified time and temperature at 37 20 C. Time for 
complete disintegration of tablet was noted down.  
d) Friability test Apparatus: Electrolab Friability tester, 
Model EF 2 Procedure: A sample of 10 tablets was taken 
and was carefully dedusted prior to testing. The tablets were 
accurately weighed and placed in the drum of the Roche 
Friabilator. The drum was rotated for 100 times at 25 rpm 
and the tablets were removed, dedusted and accurately 
weighed. % Friability calculated by following formula:  
% Friability = [(W1 – W2) / W1] × 100  
Where W1 = Initial weight of 10 tablets; W2 = Weight of the 
10 tablets after testing 
Acceptance criteria: Friability of tablets should be less than 
0.5-1% as per USP. 
e) In vitro Dissolution [15] Drug release studies were 
carried out using paddle type II dissolution test apparatus 
(900 ml, 50 rpm, 37°C ± 0.5°C) in standard buffer pH 1.2. At 
the end of the each sampling time period 5ml of the samples 
were taken and analyzed for drug content. A 5ml volume of 
fresh and filtered dissolution medium was added to make 
the volume after each sample withdrawal. After 
withdrawing, samples were filtered and analyzed after 
appropriate dilution by using Double beam UV-
spectrophotometer. The concentration was calculated using 
standard calibration curve. 
Optimization of Liquisolid Tablet Using 32 Full Factorial 
Designs and Preparation And Evaluation Of Check Point 
Batch[16] 
In order to investigate the effect of formulation variables on 
the response variables, and to predict an optimized 
formulation, a 32 factorial design was adopted. Nine batches 
were prepared as per the design layout shown in table 4. 
One optimized check-point batch was prepared on the basis 
of generated overlay plot of responses to validate the model 
generated. Checkpoint Batch was evaluated and results are 
shown in table 12 
  
Table 4: List of Different Dependent & Independent Variables 
 
Comparison of check point batch with directly 
compressible tablet (DCT) and Marketed product 
Formulated liquisolid compact of olanzapine was compared 
with DCT and marketed product. Olanzapine  tablet is 
available in the market from different companies. Marketed 
product Olexa Tab 10 mg was taken for comparison.  
Stability study of check point batch  
The tablets were stored at 25˚C and 75% relative humidity 
condition for 1 month. The stored tablets were evaluated 
using dissolution test. The dissolution data of aged tablets 
were compared with those of freshly prepared tablets. 
Stability study was carried out for one month at 25˚Cand 75 
% RH in desiccators. The tablets from the optimized batch 
were placed at 25˚C and 75 % RH for 30 days. At the end of 
30 days, the dissolution studies of tablets were carried out. 
Student t-test was applied for dissolution study at initial 
stage and after 30 days of storage, the dosage form did not 
show any significant difference (tcal< ttab.) as shown in 
table 14. 
  
 
 
 
 
 
Independent Variables  Dependent Variables   
X1  X2  Y1  Y2  Y3 
Excipient ratio 
(R value)  
Concentration of 
Drug in nonvolatile 
solvents %w/w  
Angle of 
repose  
Percentage Drug Release at 15 
minutes in standard buffer pH 
1.2  
Percentage Drug Release 
at 30 minutes in standard 
buffer pH 1.2 
-1  0  +1  -1  0  +1  
10 15  20  10  15  20 
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RESULTS AND DISCUSSIONS: 
 
Figure 1: Calibration Curve of Olanzapine in 0.1NHCl 
 
Figure 2: Calibration Curve of Olanzapine in Methanol 
 
Figure 3: Solubility of Olanzapine in different Nonvolatile solvents 
As shown in figure 3 solubility of Olanzapine is found more in PEG 400 as compared to other solvents. 
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Figure 4: XRD crystallogram of Olanzapine and Physical mixture 
Figure 4 shows the X-ray diffractograms of pure olanzapine 
and pure mixture of excipients and liquisolid formulation. 
The XRD analysis of olanzapine shows a characteristic high 
intensity peaks at 2θ value of 8.5,10, 14, 15.5,20, 22.5, and 
25. Thus, it is confirmed that the drug is in the crystalline 
state. The liquidsolid formulation shows peaks with reduced 
intensity at similar values of 2θ. This confirms that there is 
solublization of the drug present in the formulation. 
 
Figure 5: overlay FT-IR spectra of Olanzapine, Physical mixture and Liquisolid system of drug 
From the Figure 5, one can see that there is no introduction 
of any new peak in the functional group region and there 
isn’t removal of any peak in the spectra of Liquisolid 
formulation. This concludes that no functional group present 
in the drug or excipients is degraded and there is no 
formation of any new functional group. 
 
Table 5: Formulations as per 32 Full Factorial Design. 
Batch  Conc. Of 
OLZ 
%w/wa  
Rb W 
(Weight of 
liquid)  
Lf  Neusilin US2 
Q=W/Lf 
(mg)  
Aerosil 200 
q=Q/R 
(mg)  
Cross 
povidon
e 3%  
Total unit 
weight 
(mg)c  
LSC1  10  10  100  0.977  102.35 10.24 6.67 229.26 
LSC2  10  15  100  0.954 104.82 6.98  6.65 228.45 
LSC3  10  20  100  0.943  106.04 5.30  6.64 227.98 
LSC4  15  10  66.66  0.977  68.23 6.82  4.70 161.41 
LSC5  15  15  66.66  0.954  69.87 4.66  4.69 160.88 
LSC6  15  20  66.66  0.943  70.69 3.53  4.68 160.56 
LSC7  20  10  50  0.977  51.17 5.12  3.79 130.08 
LSC8  20  15  50  0.954  52.41 3.49  3.78 129.68 
LSC9  20  20  50  0.943  53.02 2.65  3.77 129.44 
a: Each tablet contains 10mg equivalent Olanzapine dissolved in PEG 400 
b: R = Carrier : Coating ratio; R = Q/q 
c: Each tablet contains Magnesium stearate 1% and Talc 2% 
Table 6: Pre compression evaluation parameters of Liquisolid system of LSC 1 to LSC 9 
Batch Bulk density  
(gm/cm3) 
Mean±SD 
 
Tapped density 
(gm/cm3) 
Mean±SD 
Angle of repose 
(Ɵ) 
Mean±SD 
 
Hausner’s ratio 
Mean±SD 
  
Carr’s index (%) 
Mean±SD 
 
LSC1  0.20 ±0.02 0.25±0.08 28.78±2.92 1.25±0.24 20±1.72 
LSC2  0.23±0.03 0.27±0.07 25.17±1.88 1.17±0.18 14.8±2.74 
LSC3  0.18±0.01 0.22±0.06 25.05±2.99 1.22±0.26 18.18±2.03 
LSC4  0.18±0.02 0.23±0.09 30.96±1.32 1.27±0.32 18.52±1.73 
LSC5  0.20±0.01 0.22±0.03 28.37±0.61 1.10±0.25 9.09±1.06 
LSC6  0.27±0.03 0.33±0.04 28.86±1.91 1.22±0.01 18.18±1.05 
LSC7  0.30±0.04 0.41±0.11 30.17±0.69 1.37±0.12 26.83±2.18 
LSC8  0.27±0.02 0.37±0.07 29.58±3.75 1.37±0.39 27.03±1.64 
LSC9  0.21±0.03 0.27±0.08 32.62±3.78 1.29±0.17 22.22±3.94 
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Hausner ratio and Carr’s index were calculated from the 
density values. The results revealed that batch LSC 2 and 5 
have Carr’s index between 9 to 15 indicates excellent and 
good flowability. The rest of the batches had fair, passable 
and poor  flowability as Carr’s index was above 16. The 
batches LSC 2 and 5 had Hausner ratio between 1.10 to 1.18 
which indicate good flowability and rest of the batches had 
fair, passable and poor flowability as hausner’s ratio was 
between 1.19 to 1.37. From the results of angle of repose 
batch LSC 1,2,3,4,5,6,7,8 which were between 25 to 30 and 
this indicates excellent flowability while LSC 9 had good 
flowability.
 
Table 7: Post compression evaluation parameters of Liquisolid system of LSC 1 to LSC 9 
Batch  Weight 
variation (mg)  
Thickness 
(mm)  
Hardness (N)  % Friability  Disintegration 
time (sec)  
% Drug 
content  
LSC1  226±1.23  2.2  57.4±1.7  0.767  180±2.7  98.53  
LSC2  224±1.33  2.2  56±1.5  0.763  175±2.4  97.12  
LSC3  224±1.45  2.2  54.2±1.32  0.760  115±3.21  96.98  
LSC4  150±1.27  1.2  59.1±1.56  0.762  179±2.55  98.95  
LSC5  150±2.56  1.2  58±2.7  0.750  165±2.9  98.62  
LSC6  150±2.15  1.2  57.9±1.45  0.749  104±3.05  98.55  
LSC7  113±1.89  1.1  58.2±1.27  0.711  118±3.65  99.95  
LSC8  100±2.98  1.1  58.6±1.3  0.620  98±2.15  99.78  
LSC9  112±2.19  1.1  57.4±1.37  0.623  99±2.69  98.56  
 
Liquisolid compacts with high R-values contain high 
amounts of Neusilin, low quantities of Aerosil 200. This is 
associated with enhanced wicking, disintegration. 
Disintegration time of LSC 3, 6, 8 and 9 was found to be 
lesser as compared to LSC 1, 2,4,5,7 in which higher amount 
of Aerosil 200 was present. Similarly, for Hardness and 
Friability also. 
  
 
Figure 6: In Vitro Dissolution Profile of Batch LSC 1 to LSC 9 in standard buffer pH 1.2 
Table 8 shows the design layout of full factorial design with response variables. The results were subjected to multiple 
regression analysis and equations were evolved. 
Table 8: Data Transformation of 32 Full Factorial Design. 
Batch Actual value  Coded 
value  
Response 
Excipient 
ratio R 
Drug concentration 
%w/w  
X1  X2  Angle of 
Repose 
(Y1)  
%Drug release 
in 15 minutes 
(Y2)  
%Drug release 
in 30 minutes 
(Y3)  
LSC 1  10  10  -1  -1  28.78 79.63 94.89 
LSC 2  10  15  0  -1  25.17  81.51 95.71 
LSC 3  10  20  1  -1  25.05  85.30 96.87 
LSC 4  15  10  -1  0  30.96 86.42 98.39 
LSC 5  15  15  0  0  28.37 91.23 99.41 
LSC 6  15  20  1  0  28.86 92.20 99.50 
LSC 7  20  10  -1  1  30.17 83.42 90.16 
LSC 8  20  15  0  1  29.58 86.31 91.21 
LSC 9  20 20  1  1  32.62 87.27 93.89 
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Discussions and Summary output of regression analysis 
Response surface methodology was used to generate a highly 
significant mathematical model, which can adequately 
describe or predict the optimization of Liquisolid tablets. 
Angle of repose, % drug release in 15 minutes and % drug 
release in 30 minutes for the nine batches (LSC 1 to LSC 9) 
showed a wide variation, i.e. 32.62 to 25.05, 79.63 to 92.20 
and 90.16 to 99.50 respectively. The data clearly indicate 
that Angle of repose and % drug release values were strongly 
dependent on the selected independent variables. The fitted 
equations relating the responses are shown in the table 6,7 
and 8 respectively. ANOVA and multiple regression analysis 
were performed using the Design Expert 8.0.7.1 trial 
software and Microsoft excels 2007.  Y = b0 + b1X1 + b2X2 + 
b12X1X2 + b11X12 + b22X22 
 
 
Figure 7: Two-Dimensional Contour Curve for Angle of repose (Y1). 
 
 
Figure 8: 3D Response Surface Curve for Angle of repose (Y1). 
Table 9: Summary output of regression analysis for effect of X1 and X2 on Y1 
Multiple R  0.9924 
R Square  0.9850 
Adjusted R Square  0.9600 
Standard Error  0.4959 
Observations  9 
 
Coefficient  Coefficient value  P-value  Level of significance  
b0  28.26 4.93E-06 ---  
b1  -0.56 0.068845 Non-significant   
b2  2.23 0.001606 Significant  
b12  1.55 0.008335 Significant 
b11  1.70 0.016748 Significant 
b22  -0.83 0.097509 Non-significant  
Equation 
Full Quadratic Model  28.26-0.56X1+2.23X2+1.70X12 -0.83X22 +1.55X1X2 
Reduced Linear Model 28.84-0.56X1+2.23X2 
Equation in terms of Actual factors 
Reduced Linear Model  23.84-0.11*R value+0.45*concentration of drug 
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Effect of X1 and X2 on Y1  
The significance level of coefficients b1 and b22 were found 
to be greater than P = 0.05 and hence they were omitted 
from the full model. For response Y1 reduced mathematical 
model was evolved omitting the insignificant terms (p>0.05) 
by adopting multiple regression analysis. The coefficients b2, 
b11 and b12 were found to be significant at P < 0.05 and 
hence they were retained. The results of the multiple linear 
regression analysis revealed that Increase in the excipient 
ratio (R value) there is decrease in angle of repose which 
may be shown by coefficient b1 bears a negative sign. 
Increase in the drug concentration there is increase in angle 
of repose which may be shown by coefficient b2 bears a 
positive sign.  
R2 value is 0.9850 which explains that about 98.50 % of 
variability is expresses by this model. Reduced model 
suggest that effect of factor on response is linear so, this is 
linear model which is shown in figure 7 and 8. 
 
Table 10: Summary output of regression analysis for effect of X1 and X2 on Y2 
Multiple R  0.9881 
R Square  0.9763 
Adjusted R Square  0.9369 
Standard Error  1.033 
Observations  9 
 
Coefficient  Coefficient value  P-value  Level of significance  
b0  90.38 1.37E-06 ---  
b1  2.55 0.009089 Significant   
b2  1.76 0.025094 Significant  
b12  -0.46 0.44349 Non-significant   
b11  -0.64 0.443575 Non-significant   
b22  -6.04 0.003705 Significant 
Equation 
Full Quadratic Model  90.38+2.55X1+1.76X2-0.64X12-6.04X22-0.46X1X2 
Reduced Linear Model 85.92+2.55X1+1.76X2 
Equation in terms of Actual factors 
Reduced Linear Model  72.99+0.51*R value+0.35*concentration of drug 
 
 
Effect of X1 and X2 on Y2  
The significance level of coefficients b11 and b12 were found 
to be greater than P = 0.05 and hence they were omitted 
from the full model. For response Y2 reduced mathematical 
model was evolved omitting the insignificant terms (p>0.05) 
by adopting multiple regression analysis. 
The coefficients b1, b2 and b22 were found to be significant 
at P < 0.05 and hence they were retained. Therefore, it was 
concluded that the interaction term do not contribute 
significantly to the prediction of % Drug release. The results 
of the multiple linear regression analysis revealed that 
Increase in the excipient ratio (R value) there is increase in 
drug release at 15 minutes which may be shown by 
coefficient b1 bears a positive sign. This may be explained by 
increase in R value there is decrease in concentration of 
Aerosil which contributes to hydrophobicity and so there is 
increased and rapid wetting of particles at higher R values, 
so there is increase in dissolution rate of drug. R2 value is 
0.9763 which shows that 97.63% of variability on response 
can be expressed by this model. Reduced model suggest that 
effect of factor on response is linear so, this is a linear model 
which is confirmed figure 9 and 10. 
 
 
Figure 9:  Two-Dimensional Contour Curve for % Drug release in 15 minutes (Y2). 
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Figure 10: 3D Response Surface Curve for % Drug release in 15 minutes (Y2). 
 
Table 11: Summary output of regression analysis for effect of X1 and X2 on Y3 
Multiple R  0.9914 
R Square  0.9829 
Adjusted R Square  0.9545 
Standard Error  0.7214 
Observations  9 
 
Coefficient  Coefficient value  P-value  Level of significance  
b0  98.98 3.53428E-07 ---  
b1  1.14 0.030740352 Significant   
b2  -2.04 0.006211909 Significant  
b12  0.44 0.311943527 Non-significant   
b11  0.17 0.756400131 Non-significant   
b22  -5.31 0.001890105 Significant 
Equation 
Full Quadratic Model  98.98+1.14X1-2.04X2+0.17X12-5.31X22-0.44X1X2 
Reduced Linear Model 95.56+1.14X1-2.04X2 
Equation in terms of Actual factors 
Reduced Linear Model  98.25+0.23*R value-0.41*concentration of drug 
 
Effect of X1 and X2 on Y3  
The significance level of coefficients b11 and b12 were found 
to be greater than P = 0.05 and hence they were omitted 
from the full model. For response Y2 reduced mathematical 
model was evolved omitting the insignificant terms (p>0.05) 
by adopting multiple regression analysis. 
The coefficients b1, b2 and b22 were found to be significant 
at P < 0.05 and hence they were retained. Therefore, it was 
concluded that the interaction term do not contribute 
significantly to the prediction of % Drug release. R2 value is 
0.9829 which shows that 98.29% of variability on response 
can be expressed by this model. Reduced model suggest that 
effect of factor on response is linear so, this is a linear model 
which is confirmed by figure 11 and 12. 
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Figure 11: Two-Dimensional Contour Curve for % drug release in 30 minutes (Y3) 
 
 
Figure 12: 3D Response Surface Curve for % Drug release in 30 minutes (Y3). 
Mathematical model validation by checkpoint batch and Optimization of the formulation 
The optimization was performed by superimposing the contour plots of the response Y1, Y2 and Y3 locating the region of 
optimal surface common as shown in Figure 13. 
 
Figure 13: Overlay plot of response variables 
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The overlay of the responses generated an optimized area, as 
per the desired criteria. The angle of repose was set in range 
25-30. The percentage drug release at 15 Min. (Y1) was set in 
range 80-90 % and % drug release at 30 min. was set in the 
range 90 -95%. These specifications satisfy the requirements 
for the good flow properties and for the immediate release 
from the dosage form. It can be concluded that by adopting a 
systemic formulation approach, one can reach to an optimum 
point in the shortest time with minimum efforts. 
 
Table 12: Preparation of Check Point Batch LSC 10 
Batch  Conc. Of 
OLZ 
%w/wa  
Rb W 
(Weight 
of liquid)  
Lf  Neusilin 
US2 
Q=W/Lf 
(mg)  
Aerosil 
200 
q=Q/R 
(mg)  
Cross 
povidone 
3%  
Total 
unit 
weight 
(mg)c  
LSC10  19.93 10.98  50.19 0.971 51.67 4.71 3.79 130.27 
 
Table 13: Comparison between the observed and predicted values 
Response Chek point batch LSC 10 
 Predicted Observed 
Angle of repose 29.97 30.17 
% drug release in 15 minutes 84.13 82.15 
% drug release in 30 minutes 90.66 91.23 
 
Observed value was found to be similar to the predicted 
values. Thus, it was confirmed that factors like concentration 
of drug and carrier to coating ratio are significant for the 
angle of repose and drug release from the formulation. Model 
generated is thus, validated. 
 
 
Figure 14: Dissolution Profile Comparison in Standard buffer pH 1.2 
 
Stability study of optimized batch LSC 10: 
The tablets were stored at 25˚C and 75% relative humidity 
condition for 1 month. The stored tablets were evaluated 
using dissolution test. The dissolution data of aged tablets 
were compared with those of freshly prepared tablets. At the 
end of 30 days, the dissolution studies of tablets were carried 
out. Student t-test was applied for dissolution study at initial 
stage and after 30 days of storage, the dosage form did not 
show any significant difference (tcal< ttab.) as shown in table 
14.
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FIGURE 15: Comparison of in- Vitro Release Profile of Batch LSC 10 Tablet Initial and after (30day) Stability Study 
 
Table 14: Student t- Test between Initial and After 30 Days of Batch LSC 10  
 
 
Student t – test between before and after 30 days of storage 
showed insignificant difference (tcal< ttab.). It conforms that 
the formulation  is stable for the time being. The developed 
dosage form passes stability study carried out for 30 days at 
25˚C and 75 % RH. 
CONCLUSION: 
The aim of the present investigation was to study the 
influence of various formulation parameters on dissolution 
rate enhancement of liquisolid compacts of olanzapine. Drug 
identification by     X-ray crystallography showed it was pure 
and crystalline in nature. PEG 400 was chosen for 
solubilization of drug.  Neusilin® and Aerosil 200 were 
chosen as carrier and coating material respectively. FT-IR 
studies show the drug compatible with excipients. 32 
factorial design was applied for optimization of formulation. 
The liquisolid tablets were formulated with three different 
drug concentrations, 10, 15, 20 %w/w, and three different 
carrier to coating ratio, 10, 15, 20. The check point batch was 
formulated and evaluated; all results were found to be in 
specified limit. The check point batch was subjected to 
stability studies for 30days and there was no remarkable 
difference was found in dissolution studies. Optimized batch, 
DCT and MKT were compared for the dissolution rate. There 
was increase drug release in Optimized batch compared to 
DCT and MKT. The improvement in dissolution contributes 
to the presence of nonvolatile solvents in the formulation 
which improves solubility and wetting properties of drug. 
From present investigation it was concluded that PEG 400 
proved to be promising liquid vehicle for formulation of 
liquisolid compacts for improvement in the dissolution of 
poorly water soluble drug. Further, it was found that tablet 
weight was considerably reduced with Neusilin®. Liquisolid 
technique is one of the promising approach for improvement 
in dissolution rate of poorly soluble drugs. 
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t-Test: Paired Two Sample for Means 
 
  Variable 1 Variable 2 
Mean 75.18034 72.53222 
Variance 917.3598 938.3531 
Observations 9 9 
Pearson Correlation 0.991225  
Hypothesized Mean Difference 0  
df 8  
t Stat 1.961664  
P(T<=t) one-tail 0.042719  
t Critical one-tail 1.859548  
P(T<=t) two-tail 0.085438  
t Critical two-tail 2.306004   
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